Fortes F P, Kuasne H, Marchi F A, Miranda P M, Rogatto S R, Achatz M I
CIPE, Laboratrio de Oncogentica Molecular, A.C. Camargo Cancer Center, São Paulo, SP, Brasil.
CIPE, Laboratrio NeoGene, A.C. Camargo Cancer Center, São Paulo, SP, Brasil.
Braz J Med Biol Res. 2015 Jul;48(7):610-5. doi: 10.1590/1414-431X20154026. Epub 2015 Apr 28.
Li-Fraumeni syndrome (LFS) is a rare, autosomal dominant, hereditary cancer predisposition disorder. In Brazil, the p.R337H TP53 founder mutation causes the variant form of LFS, Li-Fraumeni-like syndrome. The occurrence of cancer and age of disease onset are known to vary, even in patients carrying the same mutation, and several mechanisms such as genetic and epigenetic alterations may be involved in this variability. However, the extent of involvement of such events has not been clarified. It is well established that p53 regulates several pathways, including the thymine DNA glycosylase (TDG) pathway, which regulates the DNA methylation of several genes. This study aimed to identify the DNA methylation pattern of genes potentially related to the TDG pathway (CDKN2A, FOXA1, HOXD8, OCT4, SOX2, and SOX17) in 30 patients with germline TP53 mutations, 10 patients with wild-type TP53, and 10 healthy individuals. We also evaluated TDG expression in patients with adrenocortical tumors (ADR) with and without the p.R337H TP53 mutation. Gene methylation patterns of peripheral blood DNA samples assessed by pyrosequencing revealed no significant differences between the three groups. However, increased TDG expression was observed by quantitative reverse transcription PCR in p.R337H carriers with ADR. Considering the rarity of this phenotype and the relevance of these findings, further studies using a larger sample set are necessary to confirm our results.
李-弗劳梅尼综合征(LFS)是一种罕见的常染色体显性遗传性癌症易感疾病。在巴西,p.R337H TP53始祖突变导致LFS的变异形式,即李-弗劳梅尼样综合征。即使是携带相同突变的患者,癌症的发生和发病年龄也存在差异,遗传和表观遗传改变等多种机制可能与这种变异性有关。然而,这些事件的参与程度尚未明确。众所周知,p53调节多种途径,包括胸腺嘧啶DNA糖基化酶(TDG)途径,该途径调节多个基因的DNA甲基化。本研究旨在确定30例种系TP53突变患者、10例TP53野生型患者和10例健康个体中与TDG途径潜在相关的基因(CDKN2A、FOXA1、HOXD8、OCT4、SOX2和SOX17)的DNA甲基化模式。我们还评估了有和没有p.R337H TP53突变的肾上腺皮质肿瘤(ADR)患者的TDG表达。通过焦磷酸测序评估外周血DNA样本的基因甲基化模式,结果显示三组之间无显著差异。然而,定量逆转录PCR检测发现,携带p.R337H突变的ADR患者TDG表达增加。鉴于这种表型的罕见性以及这些发现的相关性,有必要使用更大的样本集进行进一步研究以证实我们的结果。